Navigation Links
New book by James Watson: Perfect for anyone who has ever learned something from a father
Date:6/5/2014

NEW YORK JUNE 5, 2014 Cold Spring Harbor Laboratory Press is pleased to announce the publication of Father to Son: Truth, Reason, and Decency by James D. Watson. The book is an engaging work that chronicles Watson's lineage through thought-provoking reflections, memorabilia, and imagery.

Many of us wonder how our heritage has influenced who we are and what we have become. The renowned scientist and author James D. Watson has more to reflect upon than most. A Radio Quiz Kid at 12 and a University of Chicago student at 15, Watson at 24 had a scientific discovery to his creditthe structure of DNAthat would win a Nobel Prize and forever change our understanding of genes and inheritance. Now, after a lifetime of accomplishment in research, writing, education, and science advocacy, Watson has delved for the first time publicly into his own lineage.

Father To Son was first intended as a small, privately published collection of the writings of his father, James D. Watson, Sr. But when Jim Watson, Jr. began investigating his family history, what emerged was a more complex storythe chronicle of an archetypical American family from before the Civil War to Vietnam. In this book, Jim Watson portrays these lives in a fascinating narrative, illustrated with previously unpublished photographs and period documents, that ends with an affectionate tribute to his father, a man of principle, decency, intelligence, and reason, from whom Jim Jr. learned liberal politics and incisive writing.

There has been warm early praise for Father to Son. "In this poignant book, Dr. Watson savors the evidence he finds about his father's life and values. It's a perfect book for anyone who has ever learned something from a father," says Walter Isaacson, author of Einstein: His Life and Universe and Steve Jobs. Hannah Holburn Gray, President Emerita at University of Chicago, commented "This is a charming and vivid book, one that a
'/>"/>

Contact: Robert Redmond
rredmond@cshl.edu
516-422-4101
Cold Spring Harbor Laboratory
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Chiltern Welcomes Cedric Burg And James Gunter
2. James Cameron to be publicly honored with Scripps Nierenberg Prize
3. Now Available -- Genome Stability: DNA Repair and Recombination by James E. Haber
4. James Wilson, M.D., Ph.D. receives Pioneer Award
5. Nutrient and toxin all at once: How plants absorb the perfect quantity of minerals
6. Farmers team with scientists to make the perfect rat trap
7. Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH
8. Bausch + Lomb übernimmt Technolas Perfect Vision GmbH
9. Bausch + Lomb to Acquire Technolas Perfect Vision GmbH
10. Bausch + Lomb adquiere Technolas Perfect Vision GmbH
11. Bausch + Lomb adquirirá Technolas Perfect Vision GmbH
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New book by James Watson: Perfect for anyone who has ever learned something from a father
(Date:7/21/2015)... GOTHENBURG, Sweden , July 21, 2015 ... sensor FPC1025. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... out of the George Washington University (GW), published in ... Sciences ( PNAS ), reveals another piece of ... behavioral diseases such as autism. Anthony-Samuel LaMantia, Ph.D., professor ... Medicine and Health Sciences (SMHS) and director of the ...
... press credentials for the American Chemical Society,s 245th National Meeting ... New Year will be held April 7-11, 2013, in New ... and others expected to gather in the Crescent City for ... from astronomy to zoology ― the meeting will offer ...
... keep their cellular calcium concentration at a very low ... many critical cellular functions (an elevated calcium concentration over ... mechanisms ensure that calcium concentration quickly returns to its ... of cellular calcium regulation underlie almost all neurodegenerative diseases. ...
Cached Biology News:GW professor discovers new information in the understanding of autism and genetics 2Press registration opens for 2013 meeting of world's largest scientific society 2
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
(Date:7/29/2015)... DIEGO , July 29, 2015  Pfenex Inc. ... 2015 financial results will be released on Thursday, August ... am Eastern Time, Pfenex management will host a conference ... business update.  A press release outlining the financial results ... the call. Please call 1-866-376-8058 (US) or ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) ... in particular, drug/device combinations. The current system received a score of 0 (range -10 ... Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... ... announced results from the RE-COVER(TM) study investigating dabigatran etexilate (150 mg ... patients with acute VTE. Results of the trial were presented ... published online in the New England Journal of Medicine .(1) ...
... , NEW YORK, Dec. 4 ... of its IL-3R targeting agents, SL-401 and SL-501, in both ... (CML) have been selected for poster presentation at the upcoming 51st ... held in New Orleans from December 5-8, 2009. The poster will ...
... , DALLAS, Dec. 3 ... Board: ACCP), today provided an update on its European commercial ... a debilitating side effect of radiation treatment and chemotherapy. MuGard ... countries, including the UK, Germany, Italy, Norway, Greece and Sweden. ...
Cached Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4
...
...
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Biology Products: